Zepp Health Corporation (ZEPP) has disclosed a new risk, in the Regulation category.
Zepp Health Corporation’s ambitions to grow through strategic acquisitions may encounter regulatory hurdles due to the PRC’s stringent controls. The 2006 Regulations on Mergers and Acquisitions, and their subsequent amendments, impose procedural complexities for foreign investors that could protract or complicate change-of-control transactions. Additionally, the Anti-Monopoly Law and the 2011 security review mandates for certain industries introduce layers of governmental approval that must be navigated. These regulatory frameworks could significantly slow down or even impede Zepp Health Corporation’s acquisition-driven expansion plans, potentially impacting its competitive edge and market presence.
The average ZEPP stock price target is $4.96, implying 483.53% upside potential.
To learn more about Zepp Health Corporation’s risk factors, click here.
